Market-access research for the vaping industry.

vapevisa

US vaping PMTAs in 2026: what two appellate rulings and FDA’s enforcement policy say

Two August 2026 opinions reached different notice-and-comment conclusions in challenges to FDA marketing denials. Read alongside FDA’s May enforcement guidance, they show why an application’s review status, an enforcement priority and a court disposition must not be treated as the same kind of market-access evidence.

Share this article

A supplier says its application is under review. Another points to FDA’s enforcement priorities. A third cites a court victory. For an electronic nicotine delivery system (ENDS) business, the first task is to identify what each document actually establishes—not to combine all three into a claim of “FDA approval.”

Two appellate opinions issued in August 2026 make that distinction particularly useful. The Ninth Circuit denied Drip More’s petition, while the Fifth Circuit granted the consolidated petitions in NicQuid and vacated the challenged order. Their reasoning concerned FDA’s comparative-efficacy requirement and the procedures used to apply it. Separately, FDA’s May guidance explains how the agency intends to allocate enforcement resources for certain unauthorized products. N23 N02 N01

Reporting basis. Sources were examined on 19 November 2026 (Asia/Shanghai). This analysis reports the 10 and 19 August opinions, the May guidance and FDA’s 28 September statement. It is not a report of complete case dockets through the verification date. The statutory edition cited below includes laws through 10 November 2026; the article does not certify all subsequent legislation or a particular product’s current legal position. S21

What the two opinions decided

Drip More: petition denied on 10 August

In Drip More LLC v. FDA, No. 21-71380, the Ninth Circuit reviewed marketing denials for flavored ENDS. The opinion describes FDA’s concern as the absence of evidence robustly and reliably evaluating the products’ beneficial impact for adult smokers compared with tobacco-flavored ENDS. N23

The court held that the denial based on the missing comparative-efficacy evidence was not arbitrary and capricious. On the separate procedural issue, it concluded that FDA was not required to undertake notice-and-comment rulemaking under either the Tobacco Control Act (TCA) or the Administrative Procedure Act (APA) before applying the requirement to Drip More’s application. The petition was denied. N23

In its APA analysis, the court emphasized that the denial affected Drip More immediately, rather than a broad class of unspecified individuals in future cases. It also reasoned that uniform or near-uniform outcomes do not necessarily transform adjudication into rulemaking. These are the court’s explanations of the challenged action—not an editorial conclusion about every future FDA denial. N23

NicQuid: order vacated and matters remanded on 19 August

Nine days later, the Fifth Circuit’s opinion in NicQuid, L.L.C. v. FDA, No. 24-60272 and consolidated cases, accepted an APA notice-and-comment challenge. It held that the comparative-efficacy standard at issue amounted to a substantive rule adopted through informal adjudication without the required notice-and-comment process. N02

The distinction within the opinion matters. It treated the arbitrary-and-capricious challenge as foreclosed by the Supreme Court’s Wages & White Lion decision, and the TCA “tobacco product standard” theory as foreclosed by the Fifth Circuit’s VDX Distro decision. The successful argument was the separate APA procedural challenge. Reporting NicQuid simply as a finding that FDA cannot require comparative evidence would lose that distinction. N02

The disposition states that the petitions are granted, the order is vacated, and the matters are remanded. The court expressly says it takes no view on what FDA or the petitioners should do on remand. That is the disposition reported here; it is not an FDA marketing-granted order. N02

The opinions therefore reached different notice-and-comment conclusions in the cases before them. This article does not decide their precedential interaction, their application to a different business, or the consequences of later proceedings. Neither a headline nor the fact of vacatur substitutes for examining the operative documents relevant to a particular product.

Product authorization is a separate question

The section 910 text examined for this report—21 U.S.C. §387j—defines a new tobacco product by reference to 15 February 2007 and specified subsequent modifications. It requires premarket review, with statutory alternatives and exceptions. For a PMTA, the public-health finding considers risks and benefits to the population as a whole, including users and nonusers; it is not merely an assessment of a manufacturer’s commercial readiness. S21

An application’s submission or progress through review is not the agency order authorizing marketing. FDA’s May guidance itself describes products marketed without required authorization as illegally marketed. FDA’s authorized-ENDS page also warns that authorization does not mean a product is safe or “FDA approved.” This report does not audit the products listed on that page or determine any supplier’s authorization status. N01 S06

For a buyer or distributor, the practical distinction is documentary: an application identifier, acceptance letter, filing status, marketing order and court opinion answer different questions. Ask for the relevant original document and match its product identity, date and terms to the claim being made.

What FDA’s May policy does—and does not—offer

FDA’s final guidance, Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization, is a nonbinding enforcement policy. The Federal Register availability notice was published on 12 May 2026 and says the guidance was immediately in effect. FDA’s guidance catalog lists the document as Final, dated 12 May. “Final” guidance does not make its recommendations a binding legislative rule or turn non-prioritization into authorization. N01 N04 R01

For ENDS marketed without authorization, the guidance says FDA generally does not intend to prioritize enforcement of the premarket-authorization requirement where its stated conditions are met:

  • The product is subject to a pending application that has been accepted and filed, or an accepted supplemental PMTA pending for more than 180 days. Footnote 7 limits the accepted-and-filed description to applications submitted on or after 4 November 2021, subject to 21 CFR 1114.27(a) and (b). Footnote 8 explains that supplemental PMTAs relate to an already authorized PMTA; the supplemental route must not be described as a blanket waiting period for every new application. N01
  • For nontobacco-flavored ENDS, FDA must also have determined that the application contains the data necessary to evaluate whether marketing would be appropriate for the protection of public health. A supplier’s own assertion that its dossier is complete is not that agency determination. N01

The qualifications are material. FDA identifies presumptively underage-appealing features—such as disguising a vape as a phone or children’s toy—as an exception to the stated non-prioritization. It also considers heightened public-health or safety concerns, including serious or unexpected adverse experiences, high nicotine content, missing required child-resistant packaging and potential fire hazards. The policy can concern disposable, cartridge-based and other ENDS; it is not a device-format exemption. N01

The guidance reserves case-by-case enforcement, gives no guarantee against action and says falling within the policy has no bearing on the likelihood of eventual premarket authorization. It also withdraws the April 2020 ENDS enforcement guidance while retaining that older document as a reference. The May document—not a surviving catalog entry for an older guidance—is the source of those statements. N01

These conditions explain why “we filed a PMTA” and “FDA generally does not prioritize this category” are not interchangeable assurances. This analysis neither verifies a product’s eligibility under the policy nor certifies the implementation or contents of the policy-information webpage described in the guidance.

FDA’s September statement was an intention, not a replacement rule

On 28 September 2026, FDA said it intended to evaluate changes to the PMTA regulatory framework, potentially through new rulemaking. The same announcement said FDA would meanwhile continue processing submissions, conducting premarket reviews and issuing decisions under the statutory requirements established by Congress. S07

That announcement is evidence of FDA’s stated intention on that date. It is not itself a replacement regulation, a grant of authorization or a determination of the effects of a particular lawsuit. This report does not claim that no later action occurred; it does not supply a complete subsequent-rulemaking history.

Questions the distinctions help a business ask

Scroll table horizontally

Claim being made Evidence to examine What the claim alone does not establish
“Our PMTA is under review” Product-specific submission, acceptance, filing and current review records A marketing-granted order or every condition of the May policy
“FDA is not prioritizing enforcement” The actual policy conditions and relevant agency communications for that product Authorization, immunity from enforcement or eventual success
“The court vacated the denial” The dated opinion, actual judgment and any relevant later orders for the case The present rights of a different party or product
“FDA is replacing the framework” The actual published instrument, its status, scope and effective dates—not only an announcement That the September statement itself changed the rules

These are evidence questions, not a checklist that makes a transaction compliant. A commercial decision may require product- and party-specific analysis beyond this report, including destination and sales-channel requirements.

Limits and worthwhile follow-up questions

The actual mandates and complete post-opinion dockets for the two appellate cases were not obtained for this report. No conclusion about current finality, later remand outcomes or the absence of subsequent proceedings is drawn from that gap. No nationwide permission, SKU-specific court protection or repeal of section 910 or the PMTA framework is asserted.

Useful follow-up questions are whether a relevant later order changes the position in the particular case, whether FDA publishes an operative replacement instrument, and what the current product-specific agency documents establish. Those questions do not undo the reportable facts in the dated opinions and policy; they identify which additional evidence a different decision would need. This article does not promise ongoing monitoring.

For regional navigation, see VapeVisa’s North America section.

Official sources